Brief: Medivir: Positive Data From Remetinostat Phase II Study In Basal Cell Carcinoma
13/05/2019 07:36
May 13 (Reuters) - Medivir AB MVIRb.ST :
* POSITIVE DATA FROM THE REMETINOSTAT PHASE II STUDY IN
BASAL CELL
CARCINOMA PRESENTED AT SID ANNUAL MEETING
* INITIAL RESULTS SUGGEST THAT REMETINOSTAT GEL OFFERS A
POTENTIALLY EFFECTIVE AND WELL-TOLERATED, NON-SURGICAL
INTERVENTION FOR TREATMENT OF LOCALIZED BCCS
Source text for Eikon: ID:nWkr2m0wMW
Further company coverage: MVIRb.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))